Fig. 3: Subgroup analyses of the coprimary efficacy endpoints.
From: Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
a–c, LSM treatment differences with 95% CIs for the coprimary efficacy endpoints by age (a), baseline RSBQ severity (b) and category of mutation severity (c) based on the MMRM analysis in the full analysis set. In a–c, data are presented as LSM treatment difference, and whiskers represent the lower and upper limits of the 95% CI; CI widths have not been adjusted for multiplicity.
